Evidence map›Paper›PMID 27015110›Full record

ArticleeLife2016

An extensive program of periodic alternative splicing linked to cell cycle progression.

Daniel Dominguez, Yi-Hsuan Tsai, Robert Weatheritt, Yang Wang, Benjamin J Blencowe, Zefeng Wang

Open access · goldAbstract read
In one paragraph

Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Daniel DominguezDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Yi-Hsuan TsaiDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Robert WeatherittDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Yang WangDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Benjamin J BlencoweDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Zefeng WangDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0002-6605-3637
University of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIST32GM007040 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS, ROBERT A · 1985 to 2019
$6.0M
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeuticsR01CA158283 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WANG, ZEFENG · 2011 to 2015
$1.4M
NCI NIH HHS R01 CA158283NIGMS NIH HHS T32 GM007040
6 · The paper itself

Abstract

Progression through the mitotic cell cycle requires periodic regulation of gene function at the levels of transcription, translation, protein-protein interactions, post-translational modification and degradation. However, the role of alternative splicing (AS) in the temporal control of cell cycle is not well understood. By sequencing the human transcriptome through two continuous cell cycles, we identify ~1300 genes with cell cycle-dependent AS changes. These genes are significantly enriched in functions linked to cell cycle control, yet they do not significantly overlap genes subject to periodic changes in steady-state transcript levels. Many of the periodically spliced genes are controlled by the SR protein kinase CLK1, whose level undergoes cell cycle-dependent fluctuations via an auto-inhibitory circuit. Disruption of CLK1 causes pleiotropic cell cycle defects and loss of proliferation, whereas CLK1 over-expression is associated with various cancers. These results thus reveal a large program of CLK1-regulated periodic AS intimately associated with cell cycle control.

Indexed as

Alternative SplicingCell CycleCell Line, TumorEpithelial CellsGene ExpressionGene Expression ProfilingGene Knockout TechniquesHumansProtein Serine-Threonine KinasesProtein-Tyrosine KinasesClk dual-specificity kinasesProtein Serine-Threonine KinasesProtein-Tyrosine Kinasesalternative splicingcancer genomiccell biologycell cycleevolutionary biologygenomicshuman

Identifiers

PMID27015110
PMCPMC4884079
OpenAlexW2307792848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.